Showing 4351-4360 of 8581 results for "".
- RoC Skincare Marks the First National Retinol Dayhttps://practicaldermatology.com/news/roc-skincare-marks-the-first-national-retinol-day/2460977/Just as Americans set back their clocks this weekend, retinol can help turn back the clock on fine lines and wrinkles. That's the message from RoC® Skincare in honor of the first-ever National Retinol Day on Sunday. National Retinol Day has been registered for annual
- European Medicines Agency Set to Review Incyte’s Ruxolitinib Cream in Vitiligohttps://practicaldermatology.com/news/european-medicines-agency-set-to-review-incytes-ruxolitinib-cream-in-vitiligo/2460970/The European Medicines Agency validated the European Marketing Authorization for Incyte’s ruxolitinib cream as a potential treatment for adolescents and adults (age >12 years) with non-segmental vitiligo with facial involvement. The validation of the Marketing Author
- Resilia Pharmaceuticals Obtains Marketing License for Solace Eczema Creamhttps://practicaldermatology.com/news/resilia-pharmaceuticals-obtains-marketing-license-for-solace-eczema-cream/2460967/Resilia Pharmaceuticals, Inc. will market and sell Solace™ Eczema Cream, a medical device, as an OTC product in the US, after signing a license agreement with Pelle Ventures, LLC. Financial terms of the transaction were not disclosed. Previously only avai
- Potential Melanoma Treatment Breakthrough: Is KDM5B the Key?https://practicaldermatology.com/news/potential-melanoma-treatment-breakthrough-is-kdm5b-the-key/2460964/The enzyme KDM5B may suppress anti-melanoma immunity, and these findings could help lead to the development of a new treatment strategy to benefit patients with melanoma and other cancers, according to a new study out of the Yale Cancer Center in New Haven, Conn. The research
- Mount Sinai Awarded $4 Million Grant to Launch Skin Biology and Diseases Resource-based Centerhttps://practicaldermatology.com/news/mount-sinai-awarded-4-million-grant-to-launch-skin-biology-and-diseases-resource-based-center/2460963/The Icahn School of Medicine at Mount Sinai is establishing a Skin Biology and Diseases Resource-based Center (SBDRC), funded by a $4 million, five-year P30 grant from the National Institutes of Health and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- EWG: UVA Protection of Most Sunscreens Just 25 Percent of Touted SPFhttps://practicaldermatology.com/news/ewg-most-sunscreens-comprise-just-25-percent-of-touted-spf/2460962/Many sunscreens offer just a quarter of their stated SPF protection against ultraviolet A rays, a new Environmental Working Group (EWG)
- Study: Laser Plus Topical Steroids May Improve VLS Symptomshttps://practicaldermatology.com/news/study-laser-plus-topical-steroids-may-improve-vls-symptoms/2460959/Adding fractional CO2 laser treatments to topical steroids may maximize treatment outcomes in refractory vulvar lichen sclerosus (VLS), according to a new study in Lasers in Surgery and
- Link Between Melanoma and Estrogen May Lead to New Therapeutic Approachhttps://practicaldermatology.com/news/link-between-melanoma-and-estrogen-may-lead-to-new-therapeutic-approach/2460953/The link between estrogens and breast cancer has long been defined, but a Duke-led research team has identified how these hormones can also influence the growth of other cancers, notably melanoma.
- Reistone’s Topical JAK Inhibitor Performs Well in Mild to Moderate ADhttps://practicaldermatology.com/news/reistones-topical-jak-inhibitor-performs-well-in-mild-to-moderate-ad/2460951/Reistone Biopharma’s SHR0302 ointment performed well in a Phase 2 study of patients with mild-to-moderate atopic dermatitis (AD), the company reports. SHR0302 ointment, a topical, selective JAK1 inhibitor, met key primary and secondary endpoints, demonstrating significant improvem
- Proscia's AI Technology Accurately Identifies Melanomas in Prospective Studyhttps://practicaldermatology.com/news/proscias-ai-technology-accurately-identifies-melanomas-in-prospective-study/2460944/Results of a prospective study just released demonstrate that an artificial intelligence (AI) technology solution from Proscia can automatically detect melanoma with a high degree of accuracy. Conducted at T